13 — HUTCHMED (China) Share News
0.000.00%
- HK$25.79bn
- HK$19.64bn
- $838.00m
- 80
- 20
- 75
- 64
REG - Hutchmed China Ltd - MAA of Fruquintinib Validated by the EMA
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Presentations at EHA and ICML
AnnouncementREG - Hutchmed China Ltd - LTIP and Share Option Scheme
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Fruquintinib NDA Granted Priority Review by FDA
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Presentations at ASCO 2023
AnnouncementREG - Hutchmed China Ltd - Standard form for notification of major holdings
AnnouncementREG - Hutchmed China Ltd - Annual General Meeting Poll Results
AnnouncementREG - Hutchmed China Ltd - Board of Directors and Board Committee Membership
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent NED
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - NDA Acceptance in China for Fruquintinib
AnnouncementRCS - Hutchmed China Ltd - Presentations at AACR Annual Meeting 2023
AnnouncementREG - Hutchmed China Ltd - Intended Retirement of Independent NED
AnnouncementREG - Hutchmed China Ltd - 2022 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Registration Phase Enrollments
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Rolling Submission of Fruquintinib US NDA Complete
Announcement